EE267 A Short-Term Cost-Effectiveness Analysis of Insulin Degludec/Insulin Aspart Versus Insulin Glargine U100 and Insulin Aspart in Patients with Type 2 Diabetes Inadequately Controlled on BASAL Insulin
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.514
https://www.valueinhealthjournal.com/article/S1098-3015(22)00715-X/fulltext
Title :
EE267 A Short-Term Cost-Effectiveness Analysis of Insulin Degludec/Insulin Aspart Versus Insulin Glargine U100 and Insulin Aspart in Patients with Type 2 Diabetes Inadequately Controlled on BASAL Insulin
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00715-X&doi=10.1016/j.jval.2022.04.514
First page :
Section Title :
Open access? :
No
Section Order :
10456